Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4
Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
Authors Weide R
Published 8 August 2008 Volume 2008:4(4) Pages 727—732
DOI https://doi.org/10.2147/TCRM.S3158
Review by Single anonymous peer review
Peer reviewer comments 5
Rudolf Weide
Praxisklinik für Hämatologie und Onkologie, Koblenz, Germany
Abstract: Bendamustine is an alkylating agent which also shows properties of a purine analog. Because of its unique mechanism of action it shows activity in relapsed indolent lymphomas which are resistant to alkylating agents, purine analogs, and rituximab. Bendamustine has a favorable toxicity profile causing no alopecia and only a moderate hematotoxicity and gastrointestinal toxicity. Combinations of bendamustine with mitoxantrone and rituximab and with rituximab alone have been shown to be highly active in relapsed/refractory indolent lymphomas and mantle cell lymphomas achieving long lasting complete remissions. Because of only moderate toxicity these combinations can be applied safely in elderly patients who can be treated in an outpatient setting.
Keywords: bendamustine, relapsed-indolent, non-Hodgkin’s lymphoma
© 2008 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.